Potential therapeutic applications of aspirin and other cyclo-oxygenase inhibitors.
1 The ubiquitous actions of the cyclo-oxygenase inhibitors are described. 2 These include the inhibitory effect on prostaglandin synthesis and the direct effect of aspirin on lymphocytes and their ability to produce lymphokines. 3 Aspirin reduces some types of platelet aggregation possibly involving inhibition of the precursors of thromboxane A2 and prostacyclin. 4 The therapeutic implications in relation to transient ischaemic attacks, coronary artery disease and reno-allograft rejection are discussed. 5 The beneficial and adverse effects on the gastro-intestinal tract are described. 6 The effects of aspirin-like drugs on the genito-urinary tract are described with particular reference to their adverse effects on labour and their therapeutic effect on dysmenorrhoea.
D000818:Animals; D001241:Aspirin / Q000627:therapeutic use*; D001792:Blood Platelets / Q000187:drug effects; D002318:Cardiovascular Diseases / Q000188:drug therapy; D016861:Cyclooxygenase Inhibitors; D004064:Digestive System / Q000187:drug effects; D006487:Hemostasis / Q000187:drug effects; D006801:Humans; D007668:Kidney / Q000502:physiology; D009369:Neoplasms / Q000503:physiopathology; D010014:Osteolysis / Q000187:drug effects; D011453:Prostaglandins / Q000502:physiology; D011652:Pulmonary Circulation / Q000187:drug effects; D012867:Skin / Q000187:drug effects; D013927:Thrombosis / Q000517:prevention & control; D014566:Urogenital System / Q000187:drug effects
D016861:Cyclooxygenase Inhibitors; D011453:Prostaglandins; D001241:Aspirin